BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed SLS catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:7401fcd8013c72c9f742@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:SLS P1/P2 readout (est.): Study of SLS009 (Formerly GFH009) a Poten
 t Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancie
 s and High-Risk Newly Diagnosed AML
DESCRIPTION:Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK
 9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly 
 Diagnosed AML\nNCT04588922 | PHASE1/PHASE2 | RECRUITING | sponsor: Sellas 
 Life Sciences Group\nPrimary completion date (ESTIMATED)\; top-line result
 s usually follow later.\nTicker SLS (confidence 0.9)\nSource: https://clin
 icaltrials.gov/study/NCT04588922\nScheduling/reference data from public re
 cords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04588922
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
